⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24835793 | 0.72 | GBA2 (0.32) | — | |
| SCHEMBL25019684 | 0.72 | — | — | |
| SCHEMBL17532935 | 0.72 | — | — | |
| SCHEMBL24836240 | 0.66 | — | — | |
| SCHEMBL19368149 | 0.65 | — | — | |
| SCHEMBL18503667 | 0.65 | — | — | |
| SCHEMBL23502394 | 0.65 | — | — | |
| SCHEMBL25839607 | 0.65 | — | — | |
| SCHEMBL25839608 | 0.65 | — | — | |
| SCHEMBL25959130 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912711-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230295170-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295169-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-09-21 | — | — | US | disclosed |